论文部分内容阅读
目的:孟鲁司特钠联合布地奈德治疗小儿咳嗽变异性哮喘的临床疗效。方法:选取100例医院收诊小儿咳嗽变异性哮喘患儿,按照数字表法随机分为观察组与对照组,观察两组的临床疗效、不良反应发生率以及治疗前后第1秒用力呼气量(FEV1)、用力肺活量(FVC)、FEV1/FVC、最大呼气流速绝对值(PEF)等方面的差异。结果:观察组有效治疗47例,治疗有效率为94.0%,对照组有效治疗38例,治疗有效率为76.0%,观察组显著优于对照组,差异有统计学意义(P<0.05);且观察组在其他方面显著优于对照组(P<0.05)。结论:孟鲁司特钠联合布地奈德在小儿咳嗽变异性哮喘中具有较好的应用效果,能够有效提高临床疗效,缓解患儿的症状,有助于提高患儿的生活质量。
Objective: Montelukast combined with budesonide in the treatment of children with cough variant asthma clinical efficacy. Methods: A total of 100 pediatric children with cough variant asthma were selected and randomly divided into observation group and control group according to the digital table method. The clinical efficacy, the incidence of adverse reactions and the forced expiratory volume in 1 second before and after treatment (FEV1), forced vital capacity (FVC), FEV1 / FVC, maximum expiratory flow velocity (PEF) and so on. Results: In the observation group, 47 cases were effectively treated, the effective rate was 94.0%, 38 cases in the control group were effective, and the effective rate was 76.0%. The observation group was significantly better than the control group (P <0.05); and The observation group was significantly better than the control group in other aspects (P <0.05). Conclusion: Montelukast combined with budesonide has a good effect in children with cough variant asthma, which can effectively improve the clinical efficacy, alleviate the symptoms of children and help to improve the quality of life of children.